Trial Profile
A randomised, placebo controlled trial of omalizumab in patients with allergic bronchopulmonary aspergillosis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Jan 2016
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Aspergillosis; Invasive bronchopulmonary aspergillosis
- Focus Therapeutic Use
- 15 Jan 2016 New trial record